Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of luvometinib plus anlotinib in KRAS-mutant metastatic non-small cell lung cancer
CTR20261499Phase 2Active
- Sponsor
- Fosun Pharma
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of luvometinib, anlotinib in non-small cell lung cancer (NSCLC), sponsored by Fosun Pharma. Started Jun 2026; status: active.
02
Drugs
luvometinibanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20261499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261499.